Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 OLE in Alzheimer's Disease
NCT07228078Phase 2Recruiting
- Sponsor
- NKGen Biotech
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of troculeucel in Alzheimer's disease (AD), sponsored by NKGen Biotech. Started Jun 2025; status: recruiting.
02
Drugs
troculeucel
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07228078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228078.